Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY save search
Metastatic Pancreatic Cancer Market to Proliferate Immensly, Predicts DelveInsight | Key Companies to Look Out for - FibroGen, AstraZeneca, Jiangsu HengRui, ImmunityBio, SynerGene, Mirati, Incyte, Astellas, AbbVie, Cue Biopharma, PureTech
Published: 2023-06-15 (Crawled : 15:00) - prnewswire.com
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -0.92%
H: 0.0%
C: -0.37%
BMEA | $11.5 -3.77% -3.91% 700K
|
Professional, Scientific, and T...
|
| O: -0.15%
H: 0.0%
C: -5.2%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.06%
H: 1.91%
C: 1.32%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.11%
H: 2.08%
C: 1.97%
companies cue cancer pancreatic market
Immune Checkpoint Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Key Companies in the Market - Regeneron, GlaxoSmithKline, Roche, Boehringer Ingelheim, AstraZeneca, Seagen, Roche
Published: 2023-06-13 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: -1.27%
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: 1.71%
H: 0.0%
C: -1.32%
XNCR | $19.08 0.85% 0.84% 450K
|
Health Technology
|
| O: 0.22%
H: 0.69%
C: 0.04%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.92%
H: 0.32%
C: -0.41%
NXTC | $1.51 -7.93% -8.61% 120K
|
Health Technology
|
| O: -2.99%
H: 4.32%
C: 1.85%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.48%
H: 1.44%
C: 0.24%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 0.18%
H: 5.8%
C: 5.1%
companies roche growth market
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors
Published: 2023-06-13 (Crawled : 11:00) - investor.alkermes.com
ENDPQ | $0.004 -50.0% 1.7M
|
n/a
|
| O: -47.17%
H: 110.71%
C: 96.43%
IRM | $75.15 0.59% 0.0% 1.2M
|
Finance
|
| O: -0.18%
H: 0.94%
C: 0.2%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.37%
H: 0.84%
C: 0.46%
AMRX | $5.46 0.18% 0.18% 1.2M
|
Health Technology
|
| O: 0.4%
H: 8.7%
C: 1.98%
ZLAB | $13.75 -4.65% -4.87% 400K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: -0.93%
VRTX | $393.1 -0.27% -0.27% 880K
|
Health Technology
|
| O: 0.08%
H: 1.04%
C: 0.36%
UTHR | $235.44 1.58% 1.55% 370K
|
Health Technology
|
| O: -0.65%
H: 2.13%
C: 1.37%
RARE | $44.11 4.25% 4.08% 890K
|
Health Technology
|
| O: 0.72%
H: 2.22%
C: 0.5%
SRPT | $117.885 0.51% 0.48% 550K
|
Health Technology
|
| O: 0.55%
H: 2.23%
C: -0.71%
SAGE | News | $12.585 -19.48% -24.2% 4.3M
|
Health Technology
|
| O: 0.07%
H: 2.89%
C: 1.85%
PTCT | News | $25.19 -0.4% -0.4% 670K
|
Health Technology
|
| O: -0.3%
H: 2.48%
C: 1.97%
PRTA 4 | $21.03 -1.45% -1.47% 460K
|
Health Technology
|
| O: 0.29%
H: 5.34%
C: 4.38%
NBIX M | $133.26 0.2% 0.2% 570K
|
Health Technology
|
| O: 0.05%
H: 2.35%
C: 2.29%
MDXG | $6.335 1.69% 1.66% 870K
|
Health Technology
|
| O: 0.85%
H: 1.34%
C: -0.17%
LPTX | $2.96 -0.67% -0.68% 150K
|
Health Technology
|
| O: 0.0%
H: 9.63%
C: 9.63%
JAZZ | News | $107.15 -1.61% -1.63% 590K
|
Health Technology
|
| O: -0.02%
H: 1.93%
C: 1.16%
IRWD | $7.66 -2.92% -3.0% 2.4M
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -3.42%
IONS | $40.93 -1.47% -1.49% 1.1M
|
Health Technology
|
| O: 0.17%
H: 1.25%
C: 0.46%
INFI | $0.016 12.5% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.76%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.48%
H: 1.44%
C: 0.24%
IDXX | $478.04 -2.36% -2.41% 530K
|
Health Technology
|
| O: 0.31%
H: 1.9%
C: 1.42%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.05%
H: 0.89%
C: 0.52%
CYCN | $3.18 12.62% 440
|
Health Technology
|
| O: 6.44%
H: 0.41%
C: -1.94%
BPMC | $88.395 2.68% 2.61% 730K
|
Health Technology
|
| O: 0.62%
H: 2.47%
C: 0.53%
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: -1.06%
H: 6.94%
C: -2.15%
ALNY | $145.23 -1.02% -1.03% 500K
|
Health Technology
|
| O: 0.07%
H: 2.64%
C: 2.23%
ALKS | News | $24.05 1.18% 1.16% 2.3M
|
Health Technology
|
| O: 0.19%
H: 1.58%
C: 0.64%
ACAD | News | $17.2 0.7% 0.7% 1M
|
Health Technology
|
| O: 0.12%
H: 1.83%
C: 1.58%
IBIO | $1.89 -3.08% 0.0% 270K
|
Health Technology
|
| O: 16.68%
H: 3.53%
C: -11.59%
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
Published: 2023-06-12 (Crawled : 20:00) - globenewswire.com
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.48%
H: 1.44%
C: 0.24%
GLPG | News | $29.25 -0.81% -0.82% 190K
|
Health Technology
|
| O: -0.92%
H: 1.29%
C: 0.55%
Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
Published: 2023-06-12 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.02%
H: 0.19%
C: -0.19%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.2%
H: 1.57%
C: 1.54%
ibi322 treatment meeting
Renal Cell Carcinoma Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies Active in the Treatment Segment - MedImmune, CRISPR, Merck, Daiichi Sankyo, Exelixis, Xencor, SOTIO, Arcus, Pfizer, Roche, AstraZeneca
Published: 2023-06-08 (Crawled : 15:00) - prnewswire.com
RCUS 4 | $14.84 -6.49% 0.0% 790K
|
Health Technology
|
| O: 0.0%
H: 5.64%
C: 5.15%
XNCR | $19.08 0.85% 0.84% 450K
|
Health Technology
|
| O: -0.33%
H: 1.52%
C: 1.34%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.18%
H: 0.41%
C: 0.02%
companies active renal cell treatment market
Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation
Published: 2023-06-08 (Crawled : 11:00) - investor.alkermes.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: -0.01%
H: 1.21%
C: 1.11%
UTHR | $235.44 1.58% 1.55% 370K
|
Health Technology
|
| O: 0.37%
H: 2.61%
C: 2.27%
RARE | $44.11 4.25% 4.08% 890K
|
Health Technology
|
| O: -0.33%
H: 1.43%
C: -0.14%
SRPT | $117.885 0.51% 0.48% 550K
|
Health Technology
|
| O: -0.4%
H: 1.32%
C: -1.16%
SAGE | News | $12.585 -19.48% -24.2% 4.3M
|
Health Technology
|
| O: -0.34%
H: 1.12%
C: 0.64%
PTCT | News | $25.19 -0.4% -0.4% 670K
|
Health Technology
|
| O: -0.48%
H: 1.54%
C: -1.87%
NBIX M | $133.26 0.2% 0.2% 570K
|
Health Technology
|
| O: 0.0%
H: 1.27%
C: 0.89%
JAZZ | News | $107.15 -1.61% -1.63% 590K
|
Health Technology
|
| O: -0.4%
H: 1.52%
C: -0.33%
IRWD | $7.66 -2.92% -3.0% 2.4M
|
Health Technology
|
| O: 0.52%
H: 0.69%
C: 0.26%
IONS | $40.93 -1.47% -1.49% 1.1M
|
Health Technology
|
| O: -0.12%
H: 3.43%
C: 2.84%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.18%
H: 0.41%
C: 0.02%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.0%
H: 1.71%
C: 0.42%
BPMC | $88.395 2.68% 2.61% 730K
|
Health Technology
|
| O: -0.9%
H: 1.07%
C: -4.84%
ALNY | $145.23 -1.02% -1.03% 500K
|
Health Technology
|
| O: 0.03%
H: 1.32%
C: 0.11%
ALKS | News | $24.05 1.18% 1.16% 2.3M
|
Health Technology
|
| O: 0.32%
H: 3.63%
C: 1.25%
ACAD | News | $17.2 0.7% 0.7% 1M
|
Health Technology
|
| O: -1.1%
H: 4.89%
C: 3.0%
presentation
Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Published: 2023-06-06 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.8%
H: 0.23%
C: -1.06%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.94%
H: 0.27%
C: 0.02%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.45%
H: 0.14%
C: -1.5%
ibi351 asco cancer meeting
Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting
Published: 2023-06-06 (Crawled : 00:00) - prnewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.94%
H: 0.27%
C: 0.02%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.45%
H: 0.14%
C: -1.5%
asco cell meeting car-t
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
Published: 2023-06-05 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.15%
H: 1.08%
C: 0.28%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.29%
H: 0.88%
C: 0.02%
ibi110 asco meeting
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
Published: 2023-06-04 (Crawled : 00:20) - prnewswire.com
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
ibi939 asco meeting
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
Published: 2023-06-02 (Crawled : 00:20) - prnewswire.com
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
| Email alert
Add to watchlist
treatment designation therapy
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
Published: 2023-06-02 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.79%
H: 1.08%
C: 0.54%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.02%
H: 1.79%
C: 1.69%
ibi351 erbitux merck germany collaboration trial china therapy
Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value
Published: 2023-05-25 (Crawled : 21:00) - investor.alkermes.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.18%
H: 0.38%
C: -0.22%
UTHR | $235.44 1.58% 1.55% 370K
|
Health Technology
|
| O: 0.0%
H: 0.84%
C: -2.27%
RARE | $44.11 4.25% 4.08% 890K
|
Health Technology
|
| O: 0.3%
H: 0.45%
C: -0.48%
SRPT | $117.885 0.51% 0.48% 550K
|
Health Technology
|
| O: -0.01%
H: 0.64%
C: -1.58%
SAGE | News | $12.585 -19.48% -24.2% 4.3M
|
Health Technology
|
| O: 0.43%
H: 2.19%
C: 1.76%
PTCT | News | $25.19 -0.4% -0.4% 670K
|
Health Technology
|
| O: -0.48%
H: 1.78%
C: -1.36%
NBIX M | $133.26 0.2% 0.2% 570K
|
Health Technology
|
| O: 0.28%
H: 1.44%
C: -1.32%
JAZZ | News | $107.15 -1.61% -1.63% 590K
|
Health Technology
|
| O: -0.32%
H: 0.51%
C: -0.98%
IRWD | $7.66 -2.92% -3.0% 2.4M
|
Health Technology
|
| O: -0.19%
H: 2.05%
C: 0.93%
IONS | $40.93 -1.47% -1.49% 1.1M
|
Health Technology
|
| O: 0.08%
H: 4.23%
C: 3.93%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.0%
H: 0.21%
C: -0.46%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: -0.05%
H: 1.47%
C: 0.58%
BPMC | $88.395 2.68% 2.61% 730K
|
Health Technology
|
| O: 0.04%
H: 6.92%
C: 6.35%
ALNY | $145.23 -1.02% -1.03% 500K
|
Health Technology
|
| O: 0.27%
H: 1.27%
C: 0.94%
ALKS | News | $24.05 1.18% 1.16% 2.3M
|
Health Technology
|
| O: 0.03%
H: 1.02%
C: -0.24%
ACAD | News | $17.2 0.7% 0.7% 1M
|
Health Technology
|
| O: -0.25%
H: 1.68%
C: 1.6%
business
Incyte to Present at Upcoming Investor Conferences - May 23, 2023
Published: 2023-05-23 (Crawled : 13:00) - biospace.com/
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.05%
H: 2.49%
C: 1.12%
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings
Published: 2023-05-17 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.49%
H: 0.03%
C: -0.3%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: -0.08%
H: 0.23%
C: -0.15%
asco trials
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
Published: 2023-05-15 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.22%
H: 0.14%
C: -0.2%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.34%
H: 1.13%
C: 1.07%
ibi351 designation
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
Published: 2023-05-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.18%
H: 0.03%
C: -0.26%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.3%
H: 0.12%
C: 0.09%
ibi362 obesity chinese study
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-05-10 (Crawled : 13:00) - biospace.com/
SYRS | $5.105 -8.18% -8.91% 130K
|
Health Technology
|
| O: 0.0%
H: 15.7%
C: 10.29%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -1.6%
update financial results
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
Published: 2023-05-10 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.54%
H: 2.89%
C: 2.31%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -1.6%
tyvyt china therapy
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.